Expert Interview
A Second Look: Discussing the potential of WEE1 inhibition to treat platinum resistant Ovarian Cancer (PROC) with a focus on Zentalis Pharmaceuticals' azenosertib and the ongoing DENALI trial
Ticker(s): ZNTL, RHHBY, GSK, BMY, LLY, AZNInstitution: University of Colorado
- Program director for Gynecologic Oncology and vice chair of education for ob/gyn department
- Manages over 50+ patients annually for ovarian cancer
- Treats a broad range of patient needs, including precancers and cancers of the cervix, ovary, uterus, vagina and vulva; Member of the Society of Gynecologic Oncologists and the American Association of Hospice and Palliative Medicine.
How many PROC patients do you manage?
Added By: wilson_adminWhat are your thoughts on WEE1 inhibition as a mechanism of action?
Added By: wilson_adminWhat would you need to see from azenosertib in DENALI to consider use over other options?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
